ABC 30 out of Fresno, Calif., reports on a clinical trial for a new blood pressure treatment called Renal Denervation.
The proposed treatment would target overactive renal nerves, which can cause blood pressure to skyrocket. Renal nerves transmit information from the kidneys to the brain. In Renal Denervation, doctors insert a needle into an artery in the groin near the kidneys and burn the nerves.
The ABC 30 story quotes a ...
continue reading...
In June, 2010, the FDA announced that it would continue to review potential risks and safety concerns of the antihypertensive medication Benicar after studies revealed serious cardiovascular risks. Now, three years later, an article on DrugInjuryWatch.com questions when the findings will be available to patients and doctors.
Two clinical trials highlighted a significantly higher rate of cardiovascular-related death in patients taking Benicar with Type 2 diabetes. Manufactured by Daiichi Sankyo, Benicar is prescribed to diminish hypertension ...
continue reading...
Reports linking the blood pressure medication Benicar to intestinal problems were a hot topic of conversation at this year’s Digestive Disease Week meeting — considered the largest and most prestigious meeting in the world for the gastrointestinal professionals.
A report in Gastroenterology and Endoscopy News says Benicar has been linked to severe symptoms similar to those of sprue, or celiac disease.
That’s not the only concern that health care professionals have raised ...
continue reading...
The U.S. Food and Drug Administration is investigating whether olmesartan-based blood pressure drugs Benicar, Azor, and Tribenzor increase the risk of enteropathy.
Benicar, known as olmesartan, an angiotensin II receptor blocker, was approved by the FDA on April 25, 2002, to treat high blood pressure. It is manufactured under the brand names Benicar, Benicar HCT, Azor, and Tribenzor.
Recently, the FDA issued a safety warning that Benicar, Azor, and Tribenzor can ...
continue reading...
An article in Forbes analyzes the likely impact of an opinion piece published in the medical journal JAMA Internal Medicine, which journalist Peter Lipson concludes is “sure to start some fights.”
In the JAMA column, retired but respected physician Iona Heath argues that mild high blood pressure is over-treated, and that medical professionals should raise the blood pressure rate at which they begin prescribing medication.
Not only might the blood ...
continue reading...
A story in The Oregonian deals with the controversial question of whether people with borderline high blood pressure are taking medicine unnecessarily.
The issue is getting a good deal of discussion in the medical community following a recent column in the journal JAMA Internal Medicine, in which a British doctor called for raising the blood pressure levels at which medication is prescribed.
Among the doctor’s concerns is that prescribing medication too ...
continue reading...
